Showing: 1 - 4 of 4 RESULTS

Mouse immune study gives pointers for development of vaccines and immune therapies — ScienceDaily

Researchers have charted the activity of tens of thousands of genes in mouse immune cells over the course of an infection. The study from the University of Melbourne, Australia, the Wellcome Sanger Institute, and their collaborators created the first full dynamic map of how cells learn to fight microbes and then preserve a memory of this for future infections.

The findings, published in the journal Nature Immunology, could help scientists develop new vaccines and therapeutics for a range of diseases by guiding their research into a particular set of immune cells, known as CD4+ T cells, that are essential for generating immunity.

The international research team studied the CD4+ T cells during an experimental infection of mice with malaria-causing parasites, which invade and multiply inside red blood cells. With the aid of machine learning techniques, the research team combined the gene activity data over four weeks of infection to

Read More

Cryometrix trailers – a potential match for Tesla electric trucks for pollution free shipping of COVID-19 Vaccines

Cryometrix CB-40 TRU

Pollution-free refrigerated trailer - no compressor, Salt Lake City, UT. PHOTO/Reflect Scientific
Pollution-free refrigerated trailer – no compressor, Salt Lake City, UT. PHOTO/Reflect Scientific
Pollution-free refrigerated trailer – no compressor, Salt Lake City, UT. PHOTO/Reflect Scientific

OREM, Utah, Oct. 12, 2020 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol:RSCF), is a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries. With several companies working towards introducing electric powered heavy-duty trucks, the Cryometrix 53-foot reefer trailer is ideally positioned to complete an all green package that replaces the diesel-powered tractor-trailers that are currently in use for transportation of goods requiring controlled temperatures.

The need for reliable cold chain management systems is becoming more evident in today’s world as we are faced with the increasing challenge of delivering perishable payloads such as pharmaceuticals and biologics to the point of use. The Cryometrix technology offers a reliable, pollution-free system with a flexible wide-ranging temperature setpoint control that can be

Read More

Carrier and AWS Collaborate to Transform How Food, Medicine, Vaccines, and Other Perishable Goods Are Moved and Monitored Globally

Carrier’s new Lynx digital platform will provide customers with greater connectivity, visibility, and intelligence across the cold chain to improve safe transport of temperature-controlled items

Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), and Carrier Global Corporation (NYSE: CARR), a leading global provider of healthy, safe, and sustainable building and cold chain solutions, announced a multi-year agreement to co-develop Carrier’s new Lynx digital platform. This suite of tools will provide Carrier customers around the world with enhanced visibility, increased connectivity, and actionable intelligence across their cold chain operations to improve outcomes for temperature-sensitive cargo, including food, medicine, and vaccines. The collaboration builds on Carrier’s selection of AWS as its preferred cloud services provider in February 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005287/en/

Carrier’s new Lynx digital platform, being co-developed with AWS, will provide Carrier customers around the world with enhanced visibility,

Read More

DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics

Award part of DARPA’s Nucleic Acids On-Demand World-Wide (NOW) initiative to develop a medical countermeasure manufacturing platform

Conference call to be held on Thursday, October 8 at 8:00 a.m. ET

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an agreement for a commitment of up to $56 million from the Defense Advanced Research Projects Agency (DARPA) to fund development of a mobile manufacturing protype leveraging Moderna’s existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. The agreement builds on a previous assistance grant with DARPA established in 2013.

The award is part of DARPA’s Nucleic Acids On Demand World-Wide (NOW) initiative to develop a mobile, end-to-end automated manufacturing platform to provide in-field, just-in-time manufacturing of Good Manufacturing Practice (GMP) quality nucleic acid (including mRNA) vaccines and therapeutics intended to

Read More